Select Page

Parkinson’s and Movement Disorders

For information on Parkinson’s and Movement Disorders clinical trials, please contact Salma Khalil

 

Current Recruiting Studies

 

Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients

From clinicaltrials.gov:
This is an open-label, postmarketing, observational study to document health outcomes, in Canadian patients with advanced Parkinson’s disease and long-term treatment with Duodopa (levodopa/carbidopa intestinal gel).

This is an open-label, postmarketing, observational study to document health outcomes, in Canadian patients with advanced Parkinson’s disease and long-term treatment with Duodopa (levodopa/carbidopa intestinal gel).

More information

A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)

From clinicaltrials.gov:
The purpose of this study is to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

More information

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson’s Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation (MOVES-PD))

From clinicaltrials.gov:
Part 1:
To determine the safety and tolerability of GZ/SAR402671 administered orally, as compared to placebo in patients with early-stage Parkinson’s disease (PD) carrying a GBA mutation or other pre-specified variants.
Part 2:
To determine the efficacy of GZ/SAR402671 administered orally daily, as compared to placebo in patients with early-stage Parkinson’s disease carrying a GBA mutation or other pre-specified variants.
Secondary Objectives:

Part 1:
To assess the pharmacokinetic (PK) profile of oral dosing of GZ/SAR4027671 in plasma when administered in early-stage Parkinson’s disease patients carrying a GBA mutation.
To assess the exposure of GZ/SAR402671 in cerebrospinal fluid (CSF) when administered in early-stage Parkinson’s disease patients carrying a GBA mutation.
Part 2:
To demonstrate overall safety and tolerability of GZ/SAR4027671 administered orally in early-stage Parkinson’s disease patients carrying a GBA mutation as compared to placebo.
To assess the pharmacodynamic response to daily oral dosing of GZ/SAR402671 in plasma and CSF as measured by glucosylceramide (GL-1) when administered in early-stage Parkinson’s disease patients carrying a GBA mutation.

The total study duration per subject in Part 2 will be approximately 168 weeks that will consist of 6.5 weeks of screening period, 52 weeks of treatment period, 104 weeks of follow-up period, and 6 weeks of post-treatment observation period. Part 1 maximal duration will be up to 48 weeks outside Japan, and up to 64 weeks in Japan.

More information